Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on September 18, 2024, through September 24, 2024. Onconetix, Inc. (ONCO), a Delaware corporation, reported a 1-for-40 reverse stock split effective September 24, 2024, and the resolution of a Nasdaq delisting notice.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or margin data. Key capital structure updates include:
- Reverse Stock Split: 1-for-40 ratio effective September 24, 2024.
- Shares Outstanding: Approximately 8,307,051 shares issued and outstanding post-split (excluding 2,656 unvested restricted shares).
- Equity Issuances:
- 142,749 shares issued to Veru Inc. upon conversion of Series A Preferred Stock.
- 6,741,820 shares issued to former Proteomedix AG stockholders upon conversion of Series B Preferred Stock.
- 513,424 units (comprising common stock and pre-funded warrants) issued to Altos Venture AG.
- 154,027 additional shares issued to Altos Venture AG upon immediate exercise of warrants.
Material Changes and Listing Status
Delisting Notice Resolution: On September 18, 2024, the Company received notice of delisting from Nasdaq for failing to maintain the $1.00 minimum bid price. On September 19, 2024, Nasdaq determined the Company would satisfy initial listing criteria (including a $4.00 minimum closing bid price) following a "change of control" triggered by the Series B Preferred Stock conversion. The delisting matter was closed.
Corporate Action: The 1-for-40 reverse stock split was implemented to comply with listing standards and facilitate the issuance of shares required by prior agreements. No fractional shares were issued; cash payments were made for fractional entitlements.
Outlook, Risks, and Unusual Items
Management Commentary: The Company confirmed that the reverse stock split and subsequent share issuances were necessary to satisfy Nasdaq listing requirements and fulfill obligations under the Share Exchange Agreement with Proteomedix and the Subscription Agreement with Altos.
Risks and Contingencies: The primary risk addressed was the potential delisting from The Nasdaq Capital Market, which was mitigated by the approved listing application and capital restructuring. The filing notes that all share amounts are presented on a post-split basis.
Investor Verification Checklist
- Verify the new CUSIP number (68237Q104) for post-split trading.
- Confirm the total share count of approximately 8.3 million shares outstanding.
- Review the terms of the pre-funded warrants issued to Altos Venture AG (Exercise price: $0.04; Term: 5 years).
- Check the Company's current stock price to ensure compliance with the $4.00 minimum closing bid price requirement approved by Nasdaq.
- Confirm the status of the 2,656 unvested restricted stock shares excluded from the outstanding total.